Brief: New Data Presented At ESMO 2022 Show Veracyte's Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions In Men With Advanced Prostate Cancer
11/09/2022 08:04
Sept 11 (Reuters) - Veracyte Inc VCYT.O :
* NEW DATA PRESENTED AT ESMO 2022 SHOW VERACYTE’S DECIPHER
PROSTATE GENOMIC CLASSIFIER MAY HELP INFORM PERSONALIZED
TREATMENT DECISIONS IN MEN WITH ADVANCED PROSTATE CANCER
* DATA SUPPORT VERACYTE'S PLAN TO EXPAND TEST AVAILABILITY
IN U.S.
AND OFFER TEST GLOBALLY AS AN IN VITRO DIAGNOSTIC
Source text for Eikon: ID:nBw3BKRMTa
Further company coverage: VCYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina